TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18260957

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg o.d.)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Fluvastatin (80 mg o.d.)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combination of Valsartan and Fluvastatin
Number of subjects: 32
Study: 15821899

Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound therapy for 20 min daily for 6 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham ultrasound device (Control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low intensity pulsed ultrasound therapy
Number of subjects: 30
Study: 11817528

Group type: EXPERIMENTAL
Intervention: Phosphorylcholine coated CPB circuit
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (uncoated CPB circuit)
Number of subjects: 20
Study: 10862437

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural pain management programme (10 half day sessions)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 58
Study: 9121849

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 164
Study: 1359139

Group type: EXPERIMENTAL
Intervention: Captopril treatment (mean daily dose 69.1 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Continuous beta-blockade
Number of subjects: 42
Study: 3913160

Group type: EXPERIMENTAL
Intervention: Pre-operative chemotherapy (tamoxifen, fluorouracil, vincristine, methotrexate, cyclophosphamide, mitoxantrone)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Perioperative radiotherapy
Number of subjects: 67
Study: 31399931

Group type: EXPERIMENTAL
Intervention: 40,000 IU of vitamin D3 per day
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 29131093

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 34
Study: 26920994

Group type: EXPERIMENTAL
Intervention: 4 ± 1 calendar days of antibiotics
Number of subjects: 112

Group type: COMPARATOR
Intervention: Maximum of 10 calendar days of therapy
Number of subjects: 112
Study: 24206578

Group type: EXPERIMENTAL
Intervention: CD56(+) APL
Number of subjects: 239

Group type: COMPARATOR
Intervention: CD56(-) APL
Number of subjects: 239
Study: 22723577

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure therapy (systolic <120 mmHg)
Number of subjects: 4687

Group type: COMPARATOR
Intervention: Standard blood pressure therapy (systolic <140 mmHg)
Number of subjects: 4687

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure therapy
Number of subjects: 4687
Study: 20109119

Group type: EXPERIMENTAL
Intervention: HIV prevention intervention
Number of subjects: 245
Study: 18485128

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All groups (Omeprazole, Pantoprazole, Lansoprazole)
Number of subjects: 24
Study: 16421033

Group type: EXPERIMENTAL
Intervention: Individualized written home-management plan
Number of subjects: 0

Group type: COMPARATOR
Intervention: No plan
Number of subjects: 0
Study: 14572191

Group type: EXPERIMENTAL
Intervention: 0.65 g/kg alcohol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10392325

Group type: COMPARATOR
Intervention: Bosentan 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bosentan 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bosentan 500 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bosentan 1000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bosentan 500 mg (with additional IV doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bosentan (all doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bosentan (doses above 500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bosentan (oral treatment phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study: 8922245

Group type: EXPERIMENTAL
Intervention: Anthracycline-containing single, alternating or 'hybrid' combination chemotherapy regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined modality regimens with chemotherapy and radiation therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single regimens of the MOPP type
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 1858176

Group type: EXPERIMENTAL
Intervention: 500 mg naproxen
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 75 mg indometacin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Day treatment with 250 mg naproxen b.i.d.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Indometacin
Number of subjects: 63
Study: 29551226

Group type: EXPERIMENTAL
Intervention: One dose of quadrivalent HPV vaccine (Gardasil™)
Number of subjects: 17729

Group type: EXPERIMENTAL
Intervention: Two doses of quadrivalent HPV vaccine (Gardasil™)
Number of subjects: 17729

Group type: EXPERIMENTAL
Intervention: Three doses of quadrivalent HPV vaccine (Gardasil™)
Number of subjects: 17729

Group type: COMPARATOR
Intervention: Unvaccinated control women
Number of subjects: 17729
Study: 26728036

Group type: EXPERIMENTAL
Intervention: Immediately loaded screws with NiTi coil
Number of subjects: 51

Group type: COMPARATOR
Intervention: Unloaded screws
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51
Study: 25065692

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 0
Study: 22592508

Group type: EXPERIMENTAL
Intervention: Ari+Val
Number of subjects: 42

Group type: COMPARATOR
Intervention: Hal+Val
Number of subjects: 42
Study: 19922703

Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical hydrocortisone
Number of subjects: 40
Study: 18408345

Group type: EXPERIMENTAL
Intervention: Nursing assistance tools (a mat with attached handles, a pair of trousers with knee pads and a waist holding belt)
Number of subjects: 41
Study: 15486338

Group type: EXPERIMENTAL
Intervention: Polysomnography
Number of subjects: 288

Group type: COMPARATOR
Intervention: Home monitoring
Number of subjects: 288
Study: 12509177

Group type: EXPERIMENTAL
Intervention: Hypermedia software presentation on basic functions of the human body
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Linear, electronic book mode
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Printed brochure
Number of subjects: 72

Group type: COMPARATOR
Intervention: Regular lectures and materials (Control group)
Number of subjects: 72
Study: 10624823

Group type: EXPERIMENTAL
Intervention: Scopolamine hydrobromide, 0.3 mg, i.v.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Glycopyrrolate, 0.2 mg, i.v.
Number of subjects: 13
Study: 8538922

Group type: EXPERIMENTAL
Intervention: Isradipine 10 mg daily for 1 week
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1934868

Group type: EXPERIMENTAL
Intervention: Folate supplementation (1 mg/day) during methotrexate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (Folate and Placebo)
Number of subjects: 0
Study: 7074555

Group type: EXPERIMENTAL
Intervention: Wide excision and immediate node dissection
Number of subjects: 553

Group type: COMPARATOR
Intervention: Wide excision and delayed node dissection
Number of subjects: 553
Study: 30734207

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg subcutaneously every 2 weeks (Q2W), with dose increase to 150 mg Q2W at week 12 if LDL-C was >= 70 mg/dl
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg Q2W
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 1257
Study: 30048657

Group type: EXPERIMENTAL
Intervention: NaF/Carb/silica, NaF/silica, NaF + MFP/chalk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NaF/Carb/silica, NaF + MFP/dical, AmF/silica
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NaF/Carb/silica, NaF + SnF2/silica/HMP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (0 ppm F)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 675 ppm F as NaF (675F-NaF) ± Carb
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NaF/carb/silica
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NaF + SnF2/silica/HMP
Number of subjects: 0
Study: 26259809

Group type: EXPERIMENTAL
Intervention: RSV F vaccine (60 or 90 µg) with or without aluminum phosphate adjuvant, 1 or 2 doses
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 24101715

Group type: EXPERIMENTAL
Intervention: Immediate therapy group using the 'Exploring Feelings' manual (Attwood, 2004) for seven weekly sessions.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Delayed therapy group (control).
Number of subjects: 32
Study: 22436198

Group type: EXPERIMENTAL
Intervention: Acyclovir (herpes simplex virus-suppressive therapy)
Number of subjects: 1305

Group type: EXPERIMENTAL
Intervention: Contraceptive use
Number of subjects: 1305
Study: 19473149

Group type: EXPERIMENTAL
Intervention: Vibration stimulus during local anaesthetic injections
Number of subjects: 0

Group type: COMPARATOR
Intervention: No vibration stimulus during local anaesthetic injections
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infiltration anaesthetic injection with vibration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Block anaesthetic injection with vibration
Number of subjects: 0
Study: 16980070

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin (n = 50)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anti-IL-2R monoclonal antibody (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 100
Study: 14666010

Group type: EXPERIMENTAL
Intervention: Total circulatory arrest
Number of subjects: 160

Group type: COMPARATOR
Intervention: Low-flow cardiopulmonary bypass
Number of subjects: 160
Study: 11200745

Group type: COMPARATOR
Intervention: Opiate abusers (group II) after treatment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Opiate abusers (group II) before and after treatment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Alcohol abusers (group I) before treatment
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study: 8775172

Group type: EXPERIMENTAL
Intervention: Shock-absorbing inserts
Number of subjects: 517

Group type: COMPARATOR
Intervention: Not issued inserts (Control)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Purchased inserts on their own
Number of subjects: 517
Study: 1469671

Group type: EXPERIMENTAL
Intervention: Reticulose
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 53
Study: 6487441

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 4 ml in 8% glucose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 4 ml in 5% glucose
Number of subjects: 30

Group type: COMPARATOR
Intervention: 0.5% bupivacaine 4 ml in 0% glucose (glucose-free solution)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine 4 ml in hyperbaric solutions (8% and 5% glucose)
Number of subjects: 30
Study: 31463720

Group type: EXPERIMENTAL
Intervention: Double-scope POEM
Number of subjects: 100

Group type: COMPARATOR
Intervention: Single-scope POEM
Number of subjects: 100
Study: 31113718

Group type: EXPERIMENTAL
Intervention: Cord blood sampling (5 mL from the placental end of the umbilical cord)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Admission blood sampling (from the neonate upon NICU admission)
Number of subjects: 80
Study: 27485803

Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine injection
Number of subjects: 52
Study: 26237827

Group type: EXPERIMENTAL
Intervention: Combined Traditional Chinese Medicine (TCM) therapy including shenfu injection (60 mL) and deproteinized calf blood injection (DCBI) (1.2 g) for Yang-Qi deficiency; shenmai injection (60 mL) and DCBI (1.2 g) for Yin-Qi deficiency, once daily for 21 days.
Number of subjects: 66

Group type: COMPARATOR
Intervention: Aricept (5 mg, once daily)
Number of subjects: 66
Study: 23748313

Group type: EXPERIMENTAL
Intervention: Permanent abutment (test group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healing abutment (control group)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 22379904

Group type: EXPERIMENTAL
Intervention: Epidural anesthesia
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Pulmonary atrium-femoral bypass
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 22
Study: 19845435

Group type: EXPERIMENTAL
Intervention: bifendate (three times daily for 14 days)
Number of subjects: 16
Study: 16953055

Group type: EXPERIMENTAL
Intervention: Sunlight exposure for one hour per day for twenty days (n=8)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation, 50,000 IU per day for twenty days (n=7)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as those not receiving either intervention)
Number of subjects: 414
Study: 14998601

Group type: EXPERIMENTAL
Intervention: Decision-aid booklet 'Birth Choices: What is best for you...vaginal or caesarean birth?'
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 21
Study: 11482555

Group type: EXPERIMENTAL
Intervention: RMT (n = 13)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (n = 15)
Number of subjects: 28
Study: 9922810

Group type: EXPERIMENTAL
Intervention: Laparoscopic total extraperitoneal repair (Group II)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Open preperitoneal herniorraphy (Group I)
Number of subjects: 64
Study: 8060584

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Trichlormethiazide
Number of subjects: 8
Study: 2647124

Group type: EXPERIMENTAL
Intervention: Short contact dithranol in stiff emulsifying ointment base
Number of subjects: 16

Group type: COMPARATOR
Intervention: Short contact dithranol in stiff Lassar's paste
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Stiff emulsifying ointment
Number of subjects: 16
Study: 29767639

Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) reduced-glycerin 1% gel applied vaginally for 14 days
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Tenofovir (TFV) reduced-glycerin 1% gel applied rectally for 14 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cervicovaginal lavage fluid and rectal fluid collected 24 hours after dosing
Number of subjects: 14
Study: 28098723

Group type: EXPERIMENTAL
Intervention: Group M (ERM removal only)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Group L (ERM and ILM removal)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (surgical dye identification)
Number of subjects: 26
Study: 26525473

Group type: COMPARATOR
Intervention: Physiological solution (group 1)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 0.05% xylometazoline solution (group 2)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 10% lidocaine solution (group 3)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 0.05% xylometazoline and 10% lidocaine mixture (group 4)
Number of subjects: 160
Study: 24117425

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Practical intervention package including intensive education, consultation services, maintenance of an epilepsy tracking card, and repeated reminders.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control Group (CG) - No intervention package.
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - Medical compliance rating.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control Group (CG) - Medical compliance rating.
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Correlation between changes in AED adherence and seizure control.
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Correlation between changes in lifestyle and seizure control.
Number of subjects: 360
Study: 21262002

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 19058678

Group type: EXPERIMENTAL
Intervention: 4-step selective enamel etching (Syntac SE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2-step self-etching adhesives
Number of subjects: 80

Group type: COMPARATOR
Intervention: Etch-and-rinse (Syntac ER)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-etching adhesives
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Self-etching adhesives under etch-and-rinse conditions
Number of subjects: 80
Study: 16689008

Group type: EXPERIMENTAL
Intervention: Total glucosides of Paeony (TGP) and leflunomide (LEF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Leflunomide (LEF) alone
Number of subjects: 80
Study: 12960786

Group type: EXPERIMENTAL
Intervention: Insufflation pressure of 8 mm Hg (LC8)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Insufflation pressure of 15 mm Hg (LC15)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (LC8 and LC15)
Number of subjects: 40
Study: 11128825

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid effervescent 1000 mg
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 9547437

Group type: EXPERIMENTAL
Intervention: Simvastatin 20-40 mg
Number of subjects: 4444

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444
Study: 8279689

Group type: EXPERIMENTAL
Intervention: Propofol (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Diazepam (n = 50)
Number of subjects: 100
Study: 3595696

Group type: EXPERIMENTAL
Intervention: Metoprolol withdrawal
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 31147972

Group type: EXPERIMENTAL
Intervention: Rectus sheath block with ropivacaine (Group B, n=25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Initial loading dose of 0.6 μg kg‐1 dexmedetomidine, followed by continuous infusion of 0.2 μg kg‐1 h‐1 (Group D, n=25)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both rectus sheath block and dexmedetomidine (Group BD, n=25)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Neither rectus sheath block nor dexmedetomidine (Group C, n=25)
Number of subjects: 100
Study: 30056782

Group type: EXPERIMENTAL
Intervention: Cuffed endotracheal tubes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Self-sealing baffled endotracheal tubes
Number of subjects: 12
Study: 27631136

Group type: EXPERIMENTAL
Intervention: Balaglitazone
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 297

Group type: COMPARATOR
Intervention: Lower tertile of endotrophin levels
Number of subjects: 297
Study: 23884342

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 22408775

Group type: EXPERIMENTAL
Intervention: At-home bleaching with 10% carbamide peroxide
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: In-office bleaching with 35% hydrogen peroxide without a light source
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: In-office bleaching with 35% hydrogen peroxide with quartz-tungsten-halogen light
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: In-office bleaching with 35% hydrogen peroxide with light-emitting diode/laser
Number of subjects: 40
Study: 19085526

Group type: EXPERIMENTAL
Intervention: Internet‐ and email‐based treatment programme for social phobia (Shyness programme)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internet treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of Internet treatment
Number of subjects: 0
Study: 17983942

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5mg/day (Livial)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16335199

Group type: EXPERIMENTAL
Intervention: Plum-blossom needle therapy combined with cupping
Number of subjects: 64

Group type: COMPARATOR
Intervention: TDP radiation
Number of subjects: 64
Study: 11966554

Group type: EXPERIMENTAL
Intervention: Sevoflurane/nitrous oxide mixture
Number of subjects: 411

Group type: COMPARATOR
Intervention: Nitrous oxide alone
Number of subjects: 411
Study: 9808914

Group type: EXPERIMENTAL
Intervention: Saffron (50 mg dissolved in 100 ml of milk, administered twice a day)
Number of subjects: 20
Study: 7695315

Group type: EXPERIMENTAL
Intervention: Quinine-clindamycin combination regimen
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Quinine-doxycycline combination regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Quinine monotherapy
Number of subjects: 100
Study: 1673134

Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg twice daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 19
Study: 37852

Group type: EXPERIMENTAL
Intervention: Oxprenolol (20 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 31866099

Group type: EXPERIMENTAL
Intervention: Mouse allergen reduction (75% or greater decrease in mouse allergen levels)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Less than 75% allergen reduction
Number of subjects: 350
Study: 31621667

Group type: EXPERIMENTAL
Intervention: PCI with postconditioning (repeated transient balloon occlusion after establishment of flow)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PCI with postconditioning
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (conventional primary PCI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 43
Study: 28882709

Group type: EXPERIMENTAL
Intervention: Full-endoscopic interlaminar approach (FEIA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Open minimally invasive microsurgical technique (MMST)
Number of subjects: 44
Study: 25992523

Group type: EXPERIMENTAL
Intervention: Bromazepam (6 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0